Rafael Dal-Ré Tenreiro chercheur
Dal-Ré Tenreiro, Rafael
VIAF ID: 68647190 (Personal)
Permalink: http://viaf.org/viaf/68647190
Preferred Forms
-
-
100 1 _ ‡a Dal-Ré Tenreiro, Rafael
-
100 1 _ ‡a Dal-Ré Tenreiro, Rafael
-
100 1 0 ‡a Dal-Ré Tenreiro, Rafael
-
100 0 _ ‡a Rafael Dal-Ré Tenreiro ‡c chercheur
4xx's: Alternate Name Forms (10)
Works
Title | Sources |
---|---|
Acequias de riego |
![]() |
Caminos rurales : proyecto y construcción |
![]() ![]() ![]() |
Concentración parcelaria y ordenación rural |
![]() |
The design can limit PRECIS─2 retrospective assessment of the clinical trial explanatory/pragmatic features |
![]() |
Do opinion articles attract more social attention than original research, relative to their citation counts? |
![]() |
[Electronic medical record in clinical trials of effectiveness of drugs integrated in clinical practice] |
![]() |
For how long and with what relevance do genetics articles retracted due to research misconduct remain active in the scientific literature |
![]() |
Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain |
![]() |
Glucose metabolism in patients with essential hypertension. |
![]() |
[High impact pediatric journals in the back stage] |
![]() |
[How long is it necessary to begin a multicentric clinical trial in Spain?] |
![]() |
Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae |
![]() |
Improving transparency of clinical trials |
![]() |
Increasing Access to FDA Inspection Reports on Irregularities and Misconduct in Clinical Trials |
![]() |
Informed consent for whole-genome sequencing studies in the clinical setting. Proposed recommendations on essential content and process |
![]() |
[Informing participants on study results and the Declaration of Helsinki 2008] |
![]() |
The International Committee of Medical Journal Editors trial data sharing requirement and participants' consent |
![]() |
International trials in middle-income countries: different local scenarios require different ethical approaches. |
![]() |
[Is it ethical conducting placebo-controlled clinical trials as part of the development of new drugs for the treatment of major depressive disorder? (I). Considerations on the value and scientific validity of the study] |
![]() |
[Is it ethically acceptable to invite a pregnant woman to enroll in a clinical trial with Tdap if it could entail not being vaccinated with Tdap before delivery?] |
![]() |
[Is it necessary to change the regulation in which drugs are not the objective of the medical research?] |
![]() |
Is the French clinical trials regulation discriminatory? |
![]() |
Journals' TOP guidelines transparency level should be disclosed. |
![]() |
Leveraging Data Science for a Personalized Haemodialysis |
![]() |
A limited number of medicines pragmatic trials had potential for waived informed consent following the 2016 CIOMS ethical guidelines |
![]() |
Making Prospective Registration of Observational Research a Reality |
![]() |
Managing incidental genomic findings in clinical trials: fulfillment of the principle of justice |
![]() |
Mandatory disclosure of financial interests of journals and editors |
![]() |
Misleading information generated in medical journals that reaches the citizen electronically |
![]() |
The misleading use of the term pragmatic in pre-licensing medicine trials |
![]() |
Modifications and waivers of informed consent and the Council for International Organizations of Medical Sciences guidelines |
![]() |
The need to implement non-industry COVID-19 clinical trials in non-high-income countries |
![]() |
Number of citations 1 year after publication of trial results and their relation to medicines regulatory approval |
![]() |
On the semantics of clinical trials. The case of a 'pragmatic' trial in Alzheimer's disease |
![]() |
Outcome reporting bias in clinical trials: why monitoring matters |
![]() |
[Participant-funded clinical trials on rare diseases] |
![]() |
Pequeños embalses de uso agrícola |
![]() ![]() |
[Pharmacogenetic studies assessment in clinical research: Four issues, four opinions]. |
![]() |
Pharmacogenetics of methylphenidate in childhood attention-deficit/hyperactivity disorder: long-term effects. |
![]() |
Plan S: Funders are committed to open access to scientific publication |
![]() |
The potential exploitation of research participants in high income countries who lack access to health care |
![]() |
The PRECIS-2 tool seems not to be useful to discriminate the degree of pragmatism of medicine masked trials from that of open-label trials |
![]() |
Preregistration and publication of nonregulated intervention trials are here to stay (letter commenting Wallach et al 2018, 93, 88-93) |
![]() |
Prestige and quality control of medical journals |
![]() |
Prevention of selective outcome reporting: let us start from the beginning |
![]() |
Protections for clinical trials in low and middle income countries need strengthening not weakening |
![]() |
[Public access to the results of clinical trials with drugs: is this enough for practicing physicians and patients?] |
![]() |
[Publications in potential predatory journals] |
![]() |
Reactogenicity profile of a combined hepatitis A and B vaccine in clinical practice: a naturalistic study in adult travellers |
![]() |
Real-world evidence: How pragmatic are randomized controlled trials labeled as pragmatic? |
![]() |
Reasons for and time to retraction of genetics articles published between 1970 and 2018 |
![]() |
[Registration of observational studies: it is time to comply with the Declaration of Helsinki requirement]. |
![]() |
Remdesivir for COVID-19 in Europe: will it provide value for money? |
![]() |
Reply to Townsend et al. |
![]() |
Reporting the details of consent procedures in clinical trials |
![]() |
[Reproducibility of biomedical research: Quo vadis?]. |
![]() |
Resistencia de materiales, construcción metálica y hormigon armado : especialidades: fitotecnia, zootecnia y economía |
![]() |
Response of preterm newborns to immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue |
![]() |
Sensitivity to change, discriminative performance, and cutoff criteria to define remission for embedded short scales of the Hamilton depression rating scale (HAMD) |
![]() |
[Should patients included in clinical trials be paid?] |
![]() |
Single research ethics committee review for multinational trials is a misconception |
![]() |
Sleep laboratory study on single and repeated dose effects of paroxetine, alprazolam and their combination in healthy young volunteers. |
![]() |
Survey of emm-like gene sequences from pharyngeal isolates of group C and group G streptococci collected in Spain |
![]() |
Time to ensure that clinical trial appropriate results are actually published |
![]() |
[Transparency of Spanish medical journals towards their readers and authors] |
![]() |
[Unified report from committes on Ethics and Clinical Investigations in multicenter trials] |
![]() |
[The unique judgement in multicenter clinical trials: the new Spanish normative in the European frame] |
![]() |
Unperceived similarities between clinical trials and quantum physics |
![]() |
Vaccine certificates for international travelers in future pandemics |
![]() |
Validación de las versiones en español de la Clinical Anxiety Scale y del Physician Questionnaire para la evaluación de los trastornos de ansiedad |
![]() |
Validation of the Spanish versions of the Montgomery-Asberg depression and Hamilton anxiety rating scales |
![]() |
Waste in COVID-19 clinical trials conducted in western Europe |
![]() |
What most influent psychiatry journals do not show |
![]() |
[When the information provided to participants of a comparative effectiveness trial ends up in the court: The opening of Pandora's box?] |
![]() |
Who are the Spanish sponsors of the higher number of non-commercial clinical trials with medicines and of the reporting of their results? |
![]() |
Who is willing to participate in low-risk pragmatic clinical trials without consent? |
![]() |
Who should be vaccinated against COVID-19 first? |
![]() |
Why prudence is needed when interpreting articles reporting clinical trial results in mental health |
![]() |
Worldwide behavioral research on major global causes of mortality |
![]() |
Worldwide clinical interventional studies on leading causes of death: a descriptive analysis |
![]() |